Investigational molecule · C-011
Retatrutide: trial evidence and unauthorised online products
The trial molecule and the online product are different evidence objects. Retatrutide has genuine human trial evidence. It is not an authorised UK medicine, and that evidence does not verify products sold under its name.
Retatrutide is an investigational triple receptor agonist studied in clinical trials. It is not authorised in the UK. The MHRA says products sold online under this name have not been assessed for safety, quality or effectiveness, and there is no guarantee that they contain retatrutide.
Seek urgent medical help through NHS 111, A&E or 999 as the situation requires. Keep the packaging and seller details if safe to do so, but do not delay care while trying to verify the product.
Claim-level evidence
Trial effect, regulatory status and product identity need separate classifications.
Weight change in adults with obesity
Limited human evidence. A phase 2 randomised trial enrolled 338 adults with obesity or overweight and a weight-related condition, excluding diabetes. Mean weight change at 48 weeks ranged from about 8.7% to 24.2% across retatrutide study groups, compared with 2.1% for placebo. A phase 2 result does not establish long-term benefit-risk or regulatory approval.
Adverse effects of the studied medicine
Limited human evidence. Gastrointestinal adverse events were the most common in phase 2 and were dose-related. Trials can characterise events within their populations and follow-up. Wider and longer safety assessment remains part of development.
Identity of a product sold online as retatrutide
No reliable evidence from the seller name alone. The MHRA states there is no guarantee an online product contains retatrutide. A suitable identity test on a traceably linked sample can answer only that analytical question.
Equivalence to the clinical-trial product
No reliable evidence identified. The trial product sits within controlled manufacture, protocol oversight and accountability. An online vial does not inherit that formulation, quality system, storage history or clinical supervision.
What the trial evidence covers
Retatrutide activates GIP, GLP-1 and glucagon receptors. The phase 2 obesity trial tested a manufactured investigational product within a randomised protocol, with eligibility rules, monitoring and predefined outcomes. That is genuine clinical evidence.
Phase 3 trials can test the medicine in larger populations and for longer periods. They do not make an online supply route lawful, and they do not authenticate products sold before approval. Trial registration also does not mean a study has reported results.
nUse known risks versus unknown risks to keep reported trial events separate from product failures and outcomes that have not yet been measured.
Use the underlying evidence records to distinguish published results from registered, ongoing or incomplete studies.
Why it cannot be lawfully supplied here as a medicine
A marketing authorisation is the regulator’s permission for a defined medicine to be supplied for specified uses under specified product information. Retatrutide has no UK marketing authorisation. In July 2026, the MHRA said selling it in the UK was illegal and warned consumers away from online products.
Clinical trials provide the lawful route to receive an investigational medicine when a person meets the study criteria and gives informed consent under an approved protocol. An online seller cannot create that route by using “research use only” on a consumer product.
Read why it cannot be lawfully supplied here and the position on buying or importing it.
What is actually being sold under this name?
| Attribute | What would support it | What does not support it |
|---|---|---|
| Identity | A suitable specific method, reference and result for a linked sample. | The listing title, label, molecular formula or seller assurance. |
| Quantity | A validated quantitative assay with units, calibration and sample link. | Chromatographic purity alone or a printed vial amount. |
| Purity profile | A suitable separation method with integration and reporting details. | A single percentage without method, chromatogram or calculation basis. |
| Sterility and endotoxin | Separate appropriate microbiological and endotoxin procedures. | Identity, purity or a seller’s “laboratory tested” phrase. |
| Clinical suitability | Regulatory assessment, product information and individual clinical assessment. | A successful trial of a different, controlled product. |
See what is actually being sold under this name in the full supply-route comparison.
Research record added 6 September 2026. The retatrutide medical-record preprint is assessed separately from the treatment trials and from sample-linked product testing. Its record retains the preliminary status and limits.
UK enforcement record
These incidents document scale and supply-route risk. They do not tell us what every seized or online item contained.
| Date | Incident | What was reported | Boundary |
|---|---|---|---|
| 24 October 2025 | Illicit weight-loss medicine production facility | More than 2,000 unlicensed retatrutide and tirzepatide pens were seized. | Seizure establishes suspected illegal manufacture and supply, not a universal composition finding. |
| 29 May 2026 | Largest MHRA seizure of unlicensed weight-loss medicines | A suspected illicit manufacturing and distribution operation was dismantled. | Regulatory action documents the route and scale. Product-by-product test results require separate evidence. |
| 24 July 2026 | National consumer warning | The MHRA stated retatrutide was unauthorised and online products were not assessed for safety, quality or effectiveness. | The warning does not convert unknown composition into a single assumed contaminant. |
Source ledger
Primary sources checked on 7 August 2026.
- Retatrutide phase 2 obesity trial, New England Journal of Medicine · randomised human efficacy and adverse-event evidence.
- TRIUMPH-1 phase 3 trial record · registered study status and design.
- MHRA: No summer shortcut for safe weight loss · UK status and consumer warning, 24 July 2026.
- MHRA record seizure, October 2025 · illicit manufacturing action involving retatrutide-labelled products.
- MHRA record seizure, May 2026 · unlicensed weight-loss medicine enforcement.
Editorial method: We log the trial molecule, authorised status and online product as separate objects. We use enforcement records to document supply activity, not to infer an unreported laboratory result.
Follow the adjacent evidence
Questions people ask
Is retatrutide approved in the UK?
No. The MHRA stated in July 2026 that retatrutide was not authorised in the UK. Lawful access to the investigational medicine is through an authorised clinical trial for eligible participants, not through ordinary online sale.
Does retatrutide cause weight loss?
A phase 2 randomised trial reported substantial mean weight reductions in adults with obesity or overweight under trial conditions. Larger and longer phase 3 studies are needed for a fuller benefit-risk assessment. Those findings do not authenticate products sold online.
Can an online laboratory certificate prove a retatrutide vial is safe?
No. A certificate may support only the attributes, methods and sample it covers. Identity or purity cannot establish quantity, sterility, endotoxin, stability, authorised manufacture, clinical suitability or the contents of an unlinked vial.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item C-011, Retatrutide: trial evidence and unauthorised online products was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 6 unique external sources and 10 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Research reference checked and reviewed · 6 September 2026. Scientific review: Eleni Kiromitis. Clinical review: Dr Stavroula Nikitopoulou. The existing evidence verdict is unchanged; earlier sources retain their own check dates.